Live Breaking News & Updates on Otago Innovation

Stay updated with breaking news from Otago innovation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments


Date Time
$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments
Amaroq Therapeutics, a new biotech start-up spun out of the University of Otago, with one of the world’s most advanced programs in next-generation RNA therapy to target cancer has secured NZ$14m investment to accelerate development.
Dr Sarah Diermeier.
The study of long non-coding RNAs (lncRNAs), often referred to as “dark matter” of the genome, are molecules naturally present in cells. Acting as key cell regulators despite not coding for proteins they have become one of the hottest areas of research globally. The emergence of new sequencing technologies has provided the opportunity to research these molecules further with significant investments being made globally into companies focusing on this area. ....

New York , United States , New Zealand , David Christensen , Sarah Diermeier , David Spector , Duncan Mackintosh , University Of Otago , Research Commercialisation Fund , Cold Spring Harbor Laboratory New York , Callaghan Innovation Technology Incubator Programme , Otago Innovation Ltd , Amaroq Therapeutics , Chief Scientific Officer , Brandon Capital , Cure Kids , Callaghan Innovation Repayable Grant , Callaghan Innovation Technology Incubator , Professor David Spector , Cold Spring Harbor Laboratory , Rutherford Discovery Fellow , Otago Innovation , Through Amaroq , Brandon Capital Managed , Medical Research Commercialisation Fund , Brandon Capital Partners ,